Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985816 | 0.90 | CYP19A1 (0.39) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL5986431 | 0.84 | EPHX1 (0.40) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL5987477 | 0.84 | EPHX1 (0.40) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL7606345 | 0.84 | EPHX1 (0.40) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL24023313 | 0.84 | EPHX1 (0.41) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL18895904 | 0.84 | EPHX1 (0.41) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL14504433 | 0.83 | KAT2B (0.33) | L3MBTL1 | |
| SCHEMBL7371640 | 0.83 | EPHX1 (0.39) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL7371636 | 0.83 | EPHX1 (0.39) | CYP19A1EPHX1NAAAHTTCYP2C19 | |
| SCHEMBL13130088 | 0.82 | EPHX1 (0.41) | CYP19A1EPHX1NAAAHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2857385-B1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | TAISHO PHARMACEUTICAL CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1204665-B1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARM INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | CYP19A1 1475/4885EPHX1 3873/4885NAAA 4867/4885 |
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | CYP19A1 1795/4885EPHX1 3727/4885NAAA 2679/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | CYP19A1 1811/4885EPHX1 4163/4885NAAA 4852/4885 |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | CYP19A1 266/4885EPHX1 4094/4885NAAA 1330/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | CYP19A1 299/4885EPHX1 3950/4885NAAA 1251/4885 |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | CYP19A1 413/4885EPHX1 3445/4885NAAA 4173/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | CYP19A1 841/4885EPHX1 3246/4885NAAA 4837/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | CYP19A1 299/4885EPHX1 3950/4885NAAA 1251/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | CYP19A1 1475/4885EPHX1 3873/4885NAAA 4867/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | CYP19A1 1005/4885EPHX1 3478/4885NAAA 4837/4885 |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | WEE1, CBR3, GLRX3 | CYP19A1 848/4885EPHX1 686/4885NAAA 2488/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | CYP19A1 413/4885EPHX1 3445/4885NAAA 4173/4885 |
| US-20210188847-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | CYP19A1 2220/4885EPHX1 3355/4885NAAA 4569/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | CYP19A1 1913/4885EPHX1 3177/4885NAAA 4565/4885 |
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | PIK3CA, AKT3, GSK3B | CYP19A1 854/4885EPHX1 1806/4885NAAA 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.